Cargando…

Multiple myeloma with t(11;14): impact of novel agents on outcome

Multiple myeloma (MM) patients with t(11;14) present unique biological features and their prognosis is not well established. We report a retrospective study of 591 MM patients, 17.3% of whom had t(11;14). It was designed to determine the prognostic impact of this abnormality and the effect of novel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Puertas, Borja, González-Calle, Verónica, Sobejano-Fuertes, Eduardo, Escalante, Fernando, Rey-Bua, Beatriz, Padilla, Irene, García-Sanz, Ramón, Puig, Noemi, Gutiérrez, Norma C., Mateos, María-Victoria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025259/ https://www.ncbi.nlm.nih.gov/pubmed/36935422 http://dx.doi.org/10.1038/s41408-023-00807-9

Ejemplares similares

Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma
por: Puertas, Borja, et al.
Publicado: (2023)

P832: PROSPECTIVE REAL-WORLD EVALUATION OF THE PREVALENCE OF T(11;14) IN MULTIPLE MYELOMA: THIRD INTERIM ANALYSIS FROM THE MEDICI STUDY
por: Gavriatopoulou, Maria, et al.
Publicado: (2023)

Incidence and effect of secondary cardiac amyloidosis on outcomes of patients with t(11;14) multiple myeloma
por: Wang, Jinghua, et al.
Publicado: (2022)

Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocation
por: Diamantidis, Michael D., et al.
Publicado: (2022)

Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)
por: Nguyen, Nina, et al.
Publicado: (2022)

Anti-BCMA CAR T-cell Therapy: Changing the Natural History of Multiple Myeloma
por: Puertas, Borja, et al.
Publicado: (2022)

Targeting BCL‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma
por: Kaufman, Jonathan L., et al.
Publicado: (2021)

Palbociclib regulates the expression of dihydrofolate reductase and the cell cycle to inhibit t (11;14) multiple myeloma
por: Wang, Yazhu, et al.
Publicado: (2022)

Is t(11;14)(q13;q32) good or bad for newly diagnosed multiple myeloma?
por: Liu, Yang, et al.
Publicado: (2023)

Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma
por: González-Calle, Verónica, et al.
Publicado: (2017)

Drug-induced Thrombotic Microangiopathy During Maintenance Treatment in a Patient With Multiple Myeloma
por: Higuero Saavedra, Víctor, et al.
Publicado: (2019)

Venetoclax for the treatment of translocation (11;14) AL amyloidosis
por: Sidiqi, M. Hasib, et al.
Publicado: (2020)

What Multiple Myeloma With t(11;14) Should Be Classified Into in Novel Agent Era: Standard or Intermediate Risk?
por: Gao, Wen, et al.
Publicado: (2020)

CD20 expression: A risk stratification factor for newly diagnosed multiple myeloma with t(11;14)
por: Jian, Yuan, et al.
Publicado: (2022)

Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma
por: Pan, Darren, et al.
Publicado: (2021)

Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers
por: Szita, Virág Réka, et al.
Publicado: (2022)

Real‐world data on safety and efficacy of venetoclax‐based regimens in relapsed/refractory t(11;14) multiple myeloma
por: Basali, Diana, et al.
Publicado: (2020)

Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2022)

Near tetrapoloid karyotype with translocation t(11;14) in a Moroccan patient with amyloid light-chain amyloidosis and multiple myeloma
por: Hamdaoui, Hasna, et al.
Publicado: (2020)

Transcriptomic Analysis in Multiple Myeloma and Primary Plasma Cell Leukemia with t(11;14) Reveals Different Expression Patterns with Biological Implications in Venetoclax Sensitivity
por: Todoerti, Katia, et al.
Publicado: (2021)

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
por: Touzeau, C, et al.
Publicado: (2014)

Multiple myeloma with t(11;14)‐associated immature phenotype has lower CD38 expression and higher BCL2 dependence
por: Kitadate, Akihiro, et al.
Publicado: (2021)

Translocation t(11;14) (q13;q32) and genomic imbalances in multi-ethnic multiple myeloma patients: a Malaysian study
por: Ni, Ivyna Bong Pau, et al.
Publicado: (2012)

The CCND1 870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma
por: Weinhold, Niels, et al.
Publicado: (2013)

Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)
por: Bahlis, Nizar J., et al.
Publicado: (2021)

T cell acute lymphoblastic leukemia with t(11;14)(p13;q11) and trisomy 8
por: Safavi, Moeinadin, et al.
Publicado: (2021)

Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis
por: Premkumar, Vikram J., et al.
Publicado: (2021)

Mantle cell lymphoma negative for t(11,14) involving the kidneys: a case report
por: Nassereldine, Hasan, et al.
Publicado: (2022)

IgE Plasma Cell Leukemia Harboring t(11;14) and 1q Amplification
por: Nakahara, Wataru, et al.
Publicado: (2023)

The prognostic impact of t(11;14) in multiple myeloma: A real‐world analysis from the Australian Lymphoma Leukaemia Group (ALLG) and the Australian Myeloma and Related Diseases Registry (MRDR)
por: Lim, Kenneth JC, et al.
Publicado: (2023)

SOX11 expression as a MRD molecular marker for MCL in comparison with t(11;14) and IGH rearrangement
por: Szostakowska, Małgorzata, et al.
Publicado: (2018)

Increased complexity of t(11;14) rearrangements in plasma cell neoplasms compared with mantle cell lymphoma
por: Dalland, Joanna C., et al.
Publicado: (2021)

Persistence of a t(11;14)‐positive clone in a patient with mantle cell lymphoma for 20 years
por: Otsuka, Yasuyuki, et al.
Publicado: (2017)

Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature
por: Abuelgasim, Khadega A., et al.
Publicado: (2020)

DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma
por: Quwaider, Dalia, et al.
Publicado: (2017)

The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl‐2 inhibitor (ABT‐199) displays synergistic anti‐myeloma effects in myeloma cells without a t(11;14) translocation
por: Sundaramoorthy, Pasupathi, et al.
Publicado: (2018)

The chromosome translocation (11;14)(p13;q11) associated with T cell acute leukemia. Asymmetric diversification of the translocational junctions
Publicado: (1990)

Outcomes of t(11;14) light chain (AL) amyloidosis after autologous stem cell transplantation: benchmark for new therapies
por: Bal, Susan, et al.
Publicado: (2023)

Induction of t(11;14) IgH enhancer/promoter-cyclin D1 gene translocation using CRISPR/Cas9
por: Tsuyama, Naohiro, et al.
Publicado: (2019)

Venetoclax in combination with chidamide and dexamethasone in relapsed/refractory primary plasma cell leukemia without t(11;14): A case report
por: Yang, Yang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gmotihbrpsgaakv7sdjoecvks8